Anavex Life Sciences Corp (AVXL)

[nidan7500]

Investor suggests a qood point on WW trial sites v belief.

That is a blow to GWP42006 but in GW’s eyes the setback isn’t terminal. The cannabinoid specialist is still planning to move the asset into the clinic in autism spectrum disorders and Rett syndrome. And it will continue to explore whether it has a future in epilepsy, despite it failing to best placebo in the phase 2a.
GW is still working to understand what drove the placebo response. But it made a point of noting the trial was mainly performed at Eastern European sites in its statement to disclose the results. Some researchers have posited a link between the globalization of clinical trials and an uptick in placebo response rates, particularly in CNS studies.

We might also consider what's next in the inevitable conflict between selected markers/RWE and precision trial results from many dark places WW.

All of this precision medicine changing trails action is positive in that we FINALLY break from the FDA/BP enclaves. But, will we see confusion on a WW scale around trial protocols and pass/fail criteria? Many, many really good questions to follow. Hey, it's a type of learning right and it is a step up from trial and error days. We get to walk the fine line between (if we do A,B,C the X will happen) vs (Just try it and see what happens). We better pay very close attention to not only what is being done but also WHERE it is being done. IMO, someone better take charge ASAP.

https://www.fiercebiotech.com/biotech/gw-cannabinoid-drug-fails-midphase-epilepsy-trial?mkt_tok=eyJpIjoiWkdObE9UWTBNVFF5TmpNeCIsInQiOiJtTjZWbzd4c0tLZEJyNkRnTHdSY2phUTBUZU52Y2Y2TVZaRGpYRFpSa3dXbkh6ZzNkeGJwdVwvSnFJRnZqSEl4eCs3T0I2K0p4aWRoQWcrd1wvYjNpVm10RWlcL0FhYTU0QzZOS09YM2hJZlJ5ZEVNT2d2ZVNNc0F0U2ZiVkhzVXlKRyJ9&mrkid=4508591